Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement: Prospective, Multi-center, Open-label, Randomized, Controlled, Investigator-Initiated Trial

NCT05431972 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT05431972
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05431972 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Cardea SOLOTM for Paroxysmal Atrial Fibrillation Diagnosis in ESUS Patients With Left Atrial Enlargement: Prospective, Multi-center, Open-label, Randomized, Controlled, Investigator-Initiated Trial
Lead sponsor
Asan Medical Center
Phase
Not applicable
Overall status
Completed
Start date
November 1, 2022
Completion date
September 13, 2024
Enrollment
257 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

embolic stroke of undetermined source